Teriparatide

ATC Code H05AA02

Teriparatide

Definition

A recombinant form of human endogenous parathyroid hormone (PTH) with an identical sequence to the 34 N-terminal amino acids of the 84-amino acid human PTH, that is used for the treatment of osteoporosis. Upon subcutaneous administration, teriparatide targets, binds to and activates parathyroid hormone receptor-1 (PTH1R), a G protein-coupled receptor (GPCR) expressed in osteoblasts and bone stromal cells. This activates the cyclic AMP (cAMP) signaling pathway and the bone anabolic signaling pathway, leading to bone growth, increased bone mineral density (BMD) and volume, which prevents or treats osteoporosis and decreases fractures.

Also known as (1-34)-Human Parathyroid Hormone, Forteo, Human PTH (1-34), Parathyroid Hormone (1-34), TERIPARATIDE — per NCIT

Also identified as

Indications

Disease Relation Source
Hypoparathyroidism may treat MEDRT · Public domain (U.S. Government work)
Postmenopausal osteoporosis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Craniocervical region may treat a disease of this organ DERIVED · CC BY 4.0
Neck may treat a disease of this organ DERIVED · CC BY 4.0
Parathyroid glands may treat a disease of this organ DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.